Logo image of CYT

CYTEIR THERAPEUTICS INC (CYT) Stock Fundamental Analysis

USA - NASDAQ:CYT - US23284P1030 - Common Stock

3.02 USD
-0.07 (-2.27%)
Last: 3/15/2024, 8:00:01 PM
3.1 USD
+0.08 (+2.65%)
After Hours: 3/15/2024, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, CYT scores 3 out of 10 in our fundamental rating. CYT was compared to 534 industry peers in the Biotechnology industry. CYT has a great financial health rating, but its profitability evaluates not so good. CYT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CYT had negative earnings in the past year.
In the past year CYT has reported a negative cash flow from operations.
CYT Yearly Net Income VS EBIT VS OCF VS FCFCYT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

CYT has a Return On Assets of -25.35%. This is in the better half of the industry: CYT outperforms 76.78% of its industry peers.
CYT's Return On Equity of -26.57% is amongst the best of the industry. CYT outperforms 82.71% of its industry peers.
Industry RankSector Rank
ROA -25.35%
ROE -26.57%
ROIC N/A
ROA(3y)-67.87%
ROA(5y)N/A
ROE(3y)-91.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYT Yearly ROA, ROE, ROICCYT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYT Yearly Profit, Operating, Gross MarginsCYT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 -50K -100K -150K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CYT has more shares outstanding
CYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CYT Yearly Shares OutstandingCYT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M
CYT Yearly Total Debt VS Total AssetsCYT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

CYT has an Altman-Z score of 9.42. This indicates that CYT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.42, CYT belongs to the top of the industry, outperforming 83.73% of the companies in the same industry.
There is no outstanding debt for CYT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.42
ROIC/WACCN/A
WACCN/A
CYT Yearly LT Debt VS Equity VS FCFCYT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 21.77 indicates that CYT has no problem at all paying its short term obligations.
The Current ratio of CYT (21.77) is better than 95.59% of its industry peers.
A Quick Ratio of 21.77 indicates that CYT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 21.77, CYT belongs to the top of the industry, outperforming 95.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 21.77
Quick Ratio 21.77
CYT Yearly Current Assets VS Current LiabilitesCYT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

CYT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.88%, which is quite impressive.
EPS 1Y (TTM)31.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CYT will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.50% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.09%
EPS Next 2Y15.07%
EPS Next 3Y10.02%
EPS Next 5Y13.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYT Yearly Revenue VS EstimatesCYT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2028 2029 2030 50M 100M 150M 200M
CYT Yearly EPS VS EstimatesCYT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CYT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYT Price Earnings VS Forward Price EarningsCYT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYT Per share dataCYT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.07%
EPS Next 3Y10.02%

More info and screens

0

5. Dividend

5.1 Amount

CYT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTEIR THERAPEUTICS INC

NASDAQ:CYT (3/15/2024, 8:00:01 PM)

After market: 3.1 +0.08 (+2.65%)

3.02

-0.07 (-2.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2024-03-13/amc
Earnings (Next)N/A N/A
Inst Owners6.83%
Inst Owner Change0%
Ins Owners25.99%
Ins Owner Change0%
Market Cap108.72M
Revenue(TTM)N/A
Net Income(TTM)-33.21M
Analysts45
Price Target3.06 (1.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.87
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0
BVpS3.47
TBVpS3.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.35%
ROE -26.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.87%
ROA(5y)N/A
ROE(3y)-91.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.77
Quick Ratio 21.77
Altman-Z 9.42
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)179.01%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.74%
EPS Next Y16.09%
EPS Next 2Y15.07%
EPS Next 3Y10.02%
EPS Next 5Y13.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.27%
EBIT Next 3Y1.26%
EBIT Next 5YN/A
FCF growth 1Y20.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.34%
OCF growth 3YN/A
OCF growth 5YN/A

CYTEIR THERAPEUTICS INC / CYT FAQ

Can you provide the ChartMill fundamental rating for CYTEIR THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to CYT.


What is the valuation status for CYT stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTEIR THERAPEUTICS INC (CYT). This can be considered as Overvalued.


What is the profitability of CYT stock?

CYTEIR THERAPEUTICS INC (CYT) has a profitability rating of 1 / 10.


How financially healthy is CYTEIR THERAPEUTICS INC?

The financial health rating of CYTEIR THERAPEUTICS INC (CYT) is 8 / 10.